{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T02:49:05Z","timestamp":1780368545607,"version":"3.54.1"},"reference-count":26,"publisher":"Becaris Publishing Limited","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            Real-world healthcare resource use (HCRU) burden among patients with Parkinson's disease psychosis (PDP) treated with pimavanserin (PIM) versus other atypical antipsychotics (other-AAPs) including quetiapine (QUE) in long term care (LTC) and nursing home (NH) settings are lacking. This analysis examines HCRU differences among residents in LTC\/NH settings who initiate PIM versus QUE or other-AAPs.\n            <jats:bold>Methods:<\/jats:bold>\n            A retrospective analysis of LTC\/NH residents with PDP from the 100% Medicare claims between 1 April 2015 and 31 December 2021 was conducted. Treatment-naive residents who initiated \u22656\u00a0months continuous monotherapy with PIM or QUE or other-AAPs between 04\/01\/16 and\u00a006\/30\/2021 were propensity score matched (PSM) 1:1 using 31 variables (age, sex, race, region and 27 Elixhauser comorbidity characteristics). Post-index (i.e., 6\u00a0months) HCRU outcomes included: proportion of residents with \u22651 all-cause inpatient (IP) hospitalizations and emergency room (ER) visits. HCRU differences were assessed via log binomial regression and reported as relative risk ratios (RR) and 95% confidence intervals after controlling for dementia, insomnia and index year.\n            <jats:bold>Results:<\/jats:bold>\n            From a total of PIM (n\u00a0=\u00a01827), QUE (n\u00a0=\u00a07770) or other-AAPs (n\u00a0=\u00a09557), 1:1 matched sample (n\u00a0=\u00a01827) in each cohort were selected. All-cause IP hospitalizations (PIM [29.8%]) versus QUE [36.7%]) and ER visits (PIM [47.3%] versus QUE [55.8%]), respectively, were significantly lower for PIM. PIM versus QUE cohort also had significantly lower RR for all-cause IP hospitalizations and ER visits, respectively, (IP hospitalizations RR: 0.82 [0.75. 0.9]; ER visits RR: 0.85 [0.8. 0.9]). PIM versus other-AAPs also had lower likelihood of HCRU outcomes.\n            <jats:bold>Conclusion:<\/jats:bold>\n            In this analysis, LTC\/NH residents on PIM monotherapy (versus QUE) had a lower likelihood of all-cause hospitalizations (18%) and ER (15%) visits. In this setting, PIM also had lower likelihood of all-cause HCRU versus other-AAPs.\n          <\/jats:p>","DOI":"10.57264\/cer-2024-0038","type":"journal-article","created":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T09:43:12Z","timestamp":1717839792000},"source":"Crossref","is-referenced-by-count":4,"title":["Healthcare resource utilization among nursing home residents with Parkinson's disease psychosis: an analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics"],"prefix":"10.57264","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4878-0822","authenticated-orcid":false,"given":"Krithika","family":"Rajagopalan","sequence":"first","affiliation":[{"name":"Anlitiks Inc.,\u00a0Windermere, FL\u00a0USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4227-1234","authenticated-orcid":false,"given":"Nazia","family":"Rashid","sequence":"additional","affiliation":[{"name":"Medical Affairs, Acadia Pharmaceuticals Inc., San Diego, CA\u00a0USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daksha","family":"Gopal","sequence":"additional","affiliation":[{"name":"Anlitiks Inc.,\u00a0Windermere, FL\u00a0USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilesh","family":"Doshi","sequence":"additional","affiliation":[{"name":"Medical Affairs, Acadia Pharmaceuticals Inc., San Diego, CA\u00a0USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"14","key":"e_1_3_7_3_2","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1056\/NEJM2003ra020003","article-title":"Alzheimer's disease and Parkinson's disease","volume":"348","author":"Nussbaum RL","year":"2003","unstructured":"Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. N. Engl. J. Med. 348(14), 1356\u20131364 (2003).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_7_4_2","unstructured":"Parkinson's Disease Foundation. https:\/\/www.parkinson.org\/understanding-parkinsons\/statistics"},{"issue":"3","key":"e_1_3_7_5_2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/mds.25292","article-title":"The current and projected economic burden of Parkinson's disease in the United States","volume":"28","author":"Kowal SL","year":"2013","unstructured":"Kowal SL, Dall TM, Chakrabarti R, Storm MV, Jain A. The current and projected economic burden of Parkinson's disease in the United States. Mov. Disord. 28(3), 311\u2013318 (2013).","journal-title":"Mov. Disord."},{"issue":"3","key":"e_1_3_7_6_2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S1353-8020(01)00015-3","article-title":"Non-recognition of depression and other non-motor symptoms in Parkinson's disease","volume":"8","author":"Shulman LM","year":"2002","unstructured":"Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat. Disord. 8(3), 193\u2013197 (2002).","journal-title":"Parkinsonism Relat. Disord."},{"issue":"3","key":"e_1_3_7_7_2","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1212\/WNL.59.3.408","article-title":"Nonmotor fluctuations in Parkinson's disease: frequent and disabling","volume":"59","author":"Witjas T","year":"2002","unstructured":"Witjas T, Kaphan E, Azulay JP Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 59(3), 408\u2013413 (2002).","journal-title":"Neurology"},{"issue":"3","key":"e_1_3_7_8_2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/archneur.60.3.387","article-title":"Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study","volume":"60","author":"Aarsland D","year":"2003","unstructured":"Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-S\u00f8rensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch. Neurol. 60(3), 387\u2013392 (2003).","journal-title":"Arch. Neurol."},{"issue":"8","key":"e_1_3_7_9_2","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/mds.21382","article-title":"Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group","volume":"22","author":"Ravina B","year":"2007","unstructured":"Ravina B, Marder K, Fernandez HH Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov. Disord. 22(8), 1061\u20131068 (2007).","journal-title":"Mov. Disord."},{"issue":"3","key":"e_1_3_7_10_2","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/mds.23462","article-title":"The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease","volume":"26","author":"Martinez-Martin P","year":"2011","unstructured":"Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR. NMSS Validation Group. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov. Disord. 26(3), 399\u2013406 (2011).","journal-title":"Mov. Disord."},{"issue":"6","key":"e_1_3_7_11_2","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/mds.21956","article-title":"The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years","volume":"23","author":"Hely MA","year":"2008","unstructured":"Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov. Disord. 23(6), 837\u2013844 (2008).","journal-title":"Mov. Disord."},{"issue":"5","key":"e_1_3_7_12_2","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/archneur.63.5.713","article-title":"The malignant course of \u201cbenign hallucinations\u201d in Parkinson disease","volume":"63","author":"Goetz CG","year":"2006","unstructured":"Goetz CG, Fan W, Leurgans S, Bernard B, Stebbins GT. The malignant course of \u201cbenign hallucinations\u201d in Parkinson disease. Arch. Neurol. 63(5), 713\u2013716 (2006).","journal-title":"Arch. Neurol."},{"issue":"2","key":"e_1_3_7_13_2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.17925\/ENR.2017.12.02.92","article-title":"Parkinson's Disease Psychosis \u2013 Patterns of Care and Treatment in the EU-5 from Neurologists' Perspective","volume":"12","author":"Cook K","year":"2017","unstructured":"Cook K, Suresh R, Lou KJ Parkinson's Disease Psychosis \u2013 Patterns of Care and Treatment in the EU-5 from Neurologists' Perspective. Eur. Neurol. Rev. 12(2), 92\u201399 (2017).","journal-title":"Eur. Neurol. Rev."},{"issue":"1","key":"e_1_3_7_14_2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jns.2009.08.014","article-title":"Epidemiology of psychosis in Parkinson's disease","volume":"289","author":"F\u00e9nelon G","year":"2010","unstructured":"F\u00e9nelon G, Alves G. Epidemiology of psychosis in Parkinson's disease. J. Neurol. Sci. 289(1\u20132), 12\u201317 (2010).","journal-title":"J. Neurol. Sci."},{"issue":"5","key":"e_1_3_7_15_2","first-page":"S83","article-title":"Parkinson's disease and Parkinson's disease psychosis: a perspective on the challenges, treatments, and economic burden","volume":"23","author":"Fredericks D","year":"2017","unstructured":"Fredericks D, Norton JC, Atchison C, Schoenhaus R, Pill MW. Parkinson's disease and Parkinson's disease psychosis: a perspective on the challenges, treatments, and economic burden. Am. J. Manag. Care 23(Suppl. 5), S83\u2013S92 (2017).","journal-title":"Am. J. Manag. Care"},{"issue":"5","key":"e_1_3_7_16_2","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1212\/WNL.0000000000001715","article-title":"Nursing home and end-of-life care in Parkinson disease","volume":"85","author":"Safarpour D","year":"2015","unstructured":"Safarpour D, Thibault DP, DeSanto CL Nursing home and end-of-life care in Parkinson disease. Neurology 85(5), 413\u2013419 (2015).","journal-title":"Neurology"},{"issue":"10","key":"e_1_3_7_17_2","first-page":"S199","article-title":"Parkinson's disease psychosis: symptoms, management, and economic burden","volume":"21","author":"Hermanowicz N","year":"2015","unstructured":"Hermanowicz N, Edwards K. Parkinson's disease psychosis: symptoms, management, and economic burden. Am. J. Manag. Care 21(Suppl. 10), S199\u2013S206 (2015).","journal-title":"Am. J. Manag. Care"},{"issue":"2","key":"e_1_3_7_18_2","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/mds.27602","article-title":"Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review [published correction appears in Mov. Disord. 34(5), 765 (2019)]","volume":"34","author":"Seppi K","year":"2019","unstructured":"Seppi K, Ray Chaudhuri K, Coelho M Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review [published correction appears in Mov. Disord. 34(5), 765 (2019)]. Mov. Disord. 34(2), 180\u2013198 (2019).","journal-title":"Mov. Disord."},{"issue":"1","key":"e_1_3_7_19_2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/13696998.2022.2152600","article-title":"Health care resource utilization patterns among patients with Parkinson's disease psychosis: analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics","volume":"26","author":"Rajagopalan K","year":"2023","unstructured":"Rajagopalan K, Rashid N, Kumar S, Doshi D. Health care resource utilization patterns among patients with Parkinson's disease psychosis: analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics. J. Med. Econ. 26(1), 34\u201342 (2023).","journal-title":"J. Med. Econ."},{"issue":"3","key":"e_1_3_7_20_2","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/mdc3.13652","article-title":"Comparison of pimavanserin versus quetiapine for hospitalization and mortality risk among medicare beneficiaries with Parkinson's disease psychosis","volume":"10","author":"Alipour-Haris G","year":"2023","unstructured":"Alipour-Haris G, Armstrong MJ, Okun M, Brown JD. Comparison of pimavanserin versus quetiapine for hospitalization and mortality risk among medicare beneficiaries with Parkinson's disease psychosis. Mov. Disord. Clin. Pract. 10(3), 406\u2013414 (2023).","journal-title":"Mov. Disord. Clin. Pract."},{"issue":"1","key":"e_1_3_7_21_2","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/13696998.2023.2220597","article-title":"Patients treated with pimavanserin or quetiapine for Parkinson's disease psychosis: analysis of health resource utilization patterns among Medicare beneficiaries","volume":"26","author":"Rajagopalan K","year":"2023","unstructured":"Rajagopalan K, Rashid N, Doshi D. Patients treated with pimavanserin or quetiapine for Parkinson's disease psychosis: analysis of health resource utilization patterns among Medicare beneficiaries. J. Med. Econ. 26(1), 769\u2013776 (2023).","journal-title":"J. Med. Econ."},{"issue":"2","key":"e_1_3_7_22_2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1176\/ajp.151.2.237","article-title":"HIV-associated psychosis: a study of 20 cases. San Diego HIV Neurobehavioral Research Center Group","volume":"151","author":"Sewell DD","year":"1994","unstructured":"Sewell DD, Jeste DV, Atkinson JH HIV-associated psychosis: a study of 20 cases. San Diego HIV Neurobehavioral Research Center Group. Am. J. Psych. 151(2), 237\u2013242 (1994).","journal-title":"Am. J. Psych."},{"key":"e_1_3_7_23_2","doi-asserted-by":"crossref","unstructured":"Beckett MK Collins RL Burnam MA Mental Health and Substance Abuse Issues Among People with HIV Lessons from HCSUS. https:\/\/www.rand.org\/pubs\/research_briefs\/RB9300.html (2007).","DOI":"10.7249\/RB9300"},{"key":"e_1_3_7_24_2","unstructured":"Substance Abuse and Mental Health Services Administration. Co-occurring disorders and other health conditions (2022). https:\/\/www.samhsa.gov\/medication-assisted-treatment\/medications-counseling-related-conditions\/co-occurring-disorders"},{"issue":"4","key":"e_1_3_7_25_2","first-page":"338","article-title":"Integrating care for people with co-occurring alcohol and other drug, medical, and mental health conditions","volume":"33","author":"Sterling S","year":"2011","unstructured":"Sterling S, Chi F, Hinman A. Integrating care for people with co-occurring alcohol and other drug, medical, and mental health conditions. Alcohol Res. Health 33(4), 338\u2013349 (2011).","journal-title":"Alcohol Res. Health"},{"issue":"11","key":"e_1_3_7_26_2","first-page":"573","article-title":"Incidence of all-cause falls and fractures among nursing facility patients treated with pimavanserin versus other atypical antipsychotics with Parkinson's disease psychosis: analysis of Medicare beneficiaries","volume":"37","author":"Rajagopalan K","year":"2022","unstructured":"Rajagopalan K, Kumar S, Rashid N, Doshi D. Incidence of all-cause falls and fractures among nursing facility patients treated with pimavanserin versus other atypical antipsychotics with Parkinson's disease psychosis: analysis of Medicare beneficiaries. Sr Care Pharm. 37(11), 573\u2013597 (2022).","journal-title":"Sr Care Pharm."},{"issue":"1","key":"e_1_3_7_27_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40801-021-00284-1","article-title":"Falls and fractures in patients with Parkinson's Disease-related psychosis treated with pimavanserin vs atypical antipsychotics: a cohort study","volume":"9","author":"Layton JB","year":"2022","unstructured":"Layton JB, Forns J, Turner ME Falls and fractures in patients with Parkinson's Disease-related psychosis treated with pimavanserin vs atypical antipsychotics: a cohort study. Drugs Real World Outcomes 9(1), 9\u201322 (2022).","journal-title":"Drugs Real World Outcomes"},{"key":"e_1_3_7_28_2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1146\/annurev.publhealth.20.1.125","article-title":"Methods for analyzing health care utilization and costs","volume":"20","author":"Diehr P","year":"1999","unstructured":"Diehr P, Yanez D, Ash A, Hornbrook M, Lin DY. Methods for analyzing health care utilization and costs. Annu. Rev. Public Health 20, 125\u2013144 (1999).","journal-title":"Annu. Rev. Public Health"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2024-0038","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T11:15:02Z","timestamp":1720091702000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2024-0038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.57264\/cer-2024-0038"],"URL":"https:\/\/doi.org\/10.57264\/cer-2024-0038","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]},"article-number":"e240038"}}